NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
NCUFirst Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma
August 20, 2025Earnings
Read more →